(FOA)-Commercializing Understudied Proteins from the Illuminating the Druggable Genome Project (IDG) (R41/R42 Clinical Trial Not Allowed); January 5, 2018

 

Agency:

National Institutes of Health (NIH)

 

Description:

The goal of this funding opportunity announcement (FOA) is to solicit applications from small business concerns (SBCs) to initiate early research ultimately leading to the commercialization of understudied proteins identified in the "Illuminating the Druggable Genome" project (IDG; https://commonfund.nih.gov/idg/index ). The purpose of the IDG is to reveal the function of selected understudied proteins in the druggable genome. Organized as a consortium, the project consists of multiple Data and Resource Generation Centers (DRGCs), a Knowledge Management Center (KMC), a Resource Dissemination and Outreach Center (RDOC) and projects developing Cutting Edge Informatics Tools (CEITs). Small businesses are expected to complement the IDG Centers by proposing projects to commercially validate reagents, data or experimental approaches. Projects could range from early proof-of-concept demonstration and assay development/validation to the initiation of preclinical drug discovery projects.

 

Activity Code:

R41/R42 Small Business Technology Transfer (STTR) Grant - Phase I, Phase II, and Fast-Track

Announcement Number:

PA-19-033

 

Closing Date:

January 5, 2019

 

Link to Full Announcement:

http://grants.nih.gov/grants/guide/pa-files/PA-19-033.html

 

Companion Funding Opportunity:

R43/R44 - http://grants.nih.gov/grants/guide/pa-files/PA-19-034.html